AUTHORS
Michael Keng, MD, Kiran Naqvi2, Timothy Pardee, MD, PhD3, Diego Adrianzen Herrara, MD MS4, Kenzo Iizuka, PhD5, Chun Zhang6, Barry Anderson, MD, PhD7
AFFILIATIONS
1 University of Virginia, Charlottesville, Virginia, United States
2 University of California Irvine, Irvine, California, United States
3 Wake Forest University, Winston-Salem, North Carolina, United States
4 University of Vermont, Burlington, Vermont, United States
5 Delta Fly Pharma, Tokushima, Japan
6 Delta Fly Pharma, Tokushima, Japan
7 Theradex Oncology, Princeton, New Jersey, United States
ABSTRACT
Background: Relapsed/refractory acute myeloid leukemia (R/R AML) remains associated with poor outcomes despite therapeutic advances. DFP-10917 is a nucleoside analog that induces DNA strand breaks after prolonged exposure and has demonstrated antileukemic activity in AML, including TP53-mutant disease. Preclinical studies suggest synergy with venetoclax. We report preliminary safety, efficacy, and pharmacokinetic (PK) results from a phase 1/2 study of DFP-10917 plus venetoclax in patients with R/R AML.
Methods: This multicenter, open-label, phase 1/2 dose-exploration and expansion study enrolled adults with R/R AML after up to 2 prior induction regimens, including venetoclax. At dose level 1, DFP-10917 4 mg/m²/day was administered by continuous intravenous infusion on Days 1-14 of each 28-day cycle, with venetoclax ramp-up to 400 mg once daily on Days 1-14. Phase 1 used a 3+3 design to evaluate dose-limiting toxicities (DLTs), adverse events, and the recommended phase 2 dose (RP2D). Phase 2 used Simon's two-stage minimax design. Overall response rate (ORR) included complete remission (CR), CR with incomplete hematologic recovery (CRi), morphologic leukemia-free state (MLFS), and partial remission (PR). If ≥3 of 10 responded in P2-stage 1, then an additional 7 pts were enrolled in P2-stage 2; ≥9 responses among 17 patients warranted further study.
Results: From September 2024 to December 2025, 30 patients were enrolled; median age was 70 years (range, 39-82), 23 (76.7%) were aged >65 years, and 21 (70.0%) were male. In phase 1, 7 patients received dose level 1; 1 withdrew consent during cycle 1 and was replaced. No DLTs occurred, and 3 responses were observed (ORR, 50.0%; 1 CR, 2 MLFS). Following Data Monitoring Committee (DMC) review, dose level -1 (DFP-10917 on Days 1-14; venetoclax on Days 1-10) was selected for expansion; dose level -2 (both agents on Days 1-10) was permitted for prolonged marrow recovery. In phase 2, 12 patients were treated in stage 1, and 2 were replaced after unrelated adverse events before response assessment. After 3 responses, the study proceeded to stage 2, in which 10 patients were treated and 3 were replaced. Among 17 evaluable patients, ORR was 52.9% (1 CR, 2 CRi, 3 MLFS, 3 PR); the DMC deemed dose level -1 safe and tolerable and recommended it for future studies. Overall, 28 patients were treated for a median of 2 cycles (range, 1-7); 20 (71.4%) had dose modifications, mainly venetoclax dose or duration adjustments for concomitant medications or tolerability. Treatment-related adverse events (TRAEs) occurred in 23 (82.1%) patients, including Grade ≥3 TRAEs in 20 (71.4%) and serious TRAEs in 2 (7.1%). The most common TRAEs were febrile neutropenia (32.1%); neutropenia and nausea (28.6% each); anemia, fatigue, and leukopenia (25.0% each); and diarrhea, thrombocytopenia, and stomatitis (21.4% each). The most common Grade ≥3 TRAEs were febrile neutropenia (32.1%), neutropenia (28.6%), leukopenia (25.0%), anemia (21.4%), thrombocytopenia, and sepsis (17.9% each). Among 23 efficacy-evaluable patients, 2 (8.7%) achieved CR, 2 (8.7%) CRi, 5 (21.7%) MLFS, and 4 (17.4%) PR, yielding a protocol-defined ORR of 56.5%. Best post-baseline aspirate and biopsy blasts were <5% in 11/23 and 8/20 patients, respectively. Two of 4 patients with CR/CRi were measurable residual disease-negative, and 4 proceeded to allogeneic hematopoietic stem cell transplantation (HSCT). At data cutoff, 3 patients remained on treatment, 18 treated patients (64.3%) had died, and 10 remained in survival follow-up. Preliminary PK analyses showed quantifiable plasma concentrations of DFP-10917 and its metabolite, CNDAU, consistent with sustained systemic exposure during infusion. Venetoclax concentrations were generally higher on Day 8 after ramp-up and repeated administration, with substantial interpatient variability.
Conclusions: DFP-10917 plus venetoclax demonstrated a manageable safety profile, no new safety signals, and preliminary antileukemic activity in a heavily pretreated R/R AML population, 80% of whom had prior venetoclax exposure. The protocol-defined ORR was 56.5%, with substantial bone marrow blast reductions, and 4 patients proceeded to allogeneic HSCT. These preliminary findings support continued evaluation of DFP-10917 plus venetoclax in R/R AML. ClinicalTrials.gov identifier: NCT06382168.
DISCLOSURES
Michael Keng, MD: No relevant conflicts of interest to declare.